Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Am Heart J. 2004 Jul; 148(1):e4.AH

Abstract

BACKGROUND

This double-blind, multicenter, randomized trial compared rosuvastatin and atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and a high risk of coronary heart disease.

METHODS

After a 6-week dietary lead-in period, patients with LDL-C levels > or =160 and <250 mg/dL and triglyceride levels < or =400 mg/dL were randomly assigned to 24 weeks' treatment in 1 of 3 groups, each with forced dose titrations at 12 and 18 weeks. Starting and titrated doses for each group were rosuvastatin 5, 20, and 80 mg (n = 127); rosuvastatin 10, 40, and 80 mg (n = 128); and atorvastatin 10, 40, and 80 mg (n = 128).

RESULTS

At 24 weeks, LDL-C was reduced significantly more with 80 mg rosuvastatin (combined rosuvastatin group) than with atorvastatin 80 mg (60% vs 52% [P <.001]). At 12 weeks, rosuvastatin 5 and 10 mg reduced LDL-C significantly more than atorvastatin 10 mg (40% [P <.01], 47% [P <.001] vs 35%). At 18 weeks, LDL-C reductions were also significantly greater in both rosuvastatin groups than in the atorvastatin group (52% [P <.01], 59% [P <.001] vs 47%). Consequently, more patients receiving rosuvastatin achieved LDL-C goals. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoproteins B and A-I, and all lipid ratios were more favorably modified by rosuvastatin at 24 weeks (P <.01). Effects of the 2 agents on triglycerides were similar.

CONCLUSIONS

Rosuvastatin was more efficacious than atorvastatin in modifying lipids in patients with hypercholesterolemia and a high coronary heart disease risk.

Authors+Show Affiliations

University of Colorado, Denver VA Medical Center, Denver, Colo 80220, USA. Gregory.Schwartz@med.va.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15215813

Citation

Schwartz, Gregory G., et al. "Efficacy and Safety of Rosuvastatin and Atorvastatin in Patients With Hypercholesterolemia and a High Risk of Coronary Heart Disease: a Randomized, Controlled Trial." American Heart Journal, vol. 148, no. 1, 2004, pp. e4.
Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004;148(1):e4.
Schwartz, G. G., Bolognese, M. A., Tremblay, B. P., Caplan, R., Hutchinson, H., Raza, A., & Cressman, M. (2004). Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. American Heart Journal, 148(1), e4.
Schwartz GG, et al. Efficacy and Safety of Rosuvastatin and Atorvastatin in Patients With Hypercholesterolemia and a High Risk of Coronary Heart Disease: a Randomized, Controlled Trial. Am Heart J. 2004;148(1):e4. PubMed PMID: 15215813.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. AU - Schwartz,Gregory G, AU - Bolognese,Michael A, AU - Tremblay,Benoit P, AU - Caplan,Richard, AU - Hutchinson,Howard, AU - Raza,Ali, AU - Cressman,Michael, PY - 2004/6/25/pubmed PY - 2004/10/6/medline PY - 2004/6/25/entrez SP - e4 EP - e4 JF - American heart journal JO - Am. Heart J. VL - 148 IS - 1 N2 - BACKGROUND: This double-blind, multicenter, randomized trial compared rosuvastatin and atorvastatin for reducing low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia and a high risk of coronary heart disease. METHODS: After a 6-week dietary lead-in period, patients with LDL-C levels > or =160 and <250 mg/dL and triglyceride levels < or =400 mg/dL were randomly assigned to 24 weeks' treatment in 1 of 3 groups, each with forced dose titrations at 12 and 18 weeks. Starting and titrated doses for each group were rosuvastatin 5, 20, and 80 mg (n = 127); rosuvastatin 10, 40, and 80 mg (n = 128); and atorvastatin 10, 40, and 80 mg (n = 128). RESULTS: At 24 weeks, LDL-C was reduced significantly more with 80 mg rosuvastatin (combined rosuvastatin group) than with atorvastatin 80 mg (60% vs 52% [P <.001]). At 12 weeks, rosuvastatin 5 and 10 mg reduced LDL-C significantly more than atorvastatin 10 mg (40% [P <.01], 47% [P <.001] vs 35%). At 18 weeks, LDL-C reductions were also significantly greater in both rosuvastatin groups than in the atorvastatin group (52% [P <.01], 59% [P <.001] vs 47%). Consequently, more patients receiving rosuvastatin achieved LDL-C goals. Total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoproteins B and A-I, and all lipid ratios were more favorably modified by rosuvastatin at 24 weeks (P <.01). Effects of the 2 agents on triglycerides were similar. CONCLUSIONS: Rosuvastatin was more efficacious than atorvastatin in modifying lipids in patients with hypercholesterolemia and a high coronary heart disease risk. SN - 1097-6744 UR - https://www.unboundmedicine.com/medline/citation/15215813/Efficacy_and_safety_of_rosuvastatin_and_atorvastatin_in_patients_with_hypercholesterolemia_and_a_high_risk_of_coronary_heart_disease:_a_randomized_controlled_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S000287030400105X DB - PRIME DP - Unbound Medicine ER -